Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Exelixis
Exelixis
2 Big Reasons Exelixis, Inc. Soared 22% in January
Motley Fool
Thu, 02/2/17 - 09:17 am
Exelixis
Cotellic
Roche
cabozantinib
Takeda
On a deal spree, Takeda grabs Japanese cabo rights in $145M pact with Exelixis
Endpoints
Tue, 01/31/17 - 09:59 am
Takeda
Japan
cabozantinib
Exelixis
Biotech Stocks: What to Watch in 2017
Motley Fool
Sun, 01/1/17 - 11:33 am
biotech
Seattle Genetics
Exelixis
Clovis Oncology
Kite Pharma
The Best Biopharma CEOs of 2016 Are...
TheStreet.com
Mon, 12/19/16 - 11:56 am
Pharma CEOs
Ken Frazier
Merck
David Hung
Medivation
Scott Jackson
Celator Pharmaceuticals
Ed Kaye
Sarepta Therapeutics
Mike Morrissey
Exelixis
The 5 Best Biotech Stocks of 2016
Motley Fool
Thu, 12/1/16 - 10:27 am
biotech
biotech stocks
AXIM Biotech
CoLucid Pharmaceuticals
Corbus
Exelixis
Tesarao
What's Pfizer's Excuse for Not Buying Exelixis?
Motley Fool
Wed, 11/30/16 - 09:46 pm
Pfizer
Exelixis
M&A
Cabometyx
kidney cancer
Sutent
3 Things Exelixis Must Do to Survive and Thrive in 2017
Motley Fool
Thu, 11/17/16 - 04:43 pm
Exelixis
cabozantinib
Cabometyx
Cometriq
5 Reasons Exelixis's Cabometyx Is Set To Be The Next Blockbuster Opportunity
Seeking Alpha
Thu, 11/10/16 - 10:59 am
Exelixis
Cabometyx
renal cell carcinoma
Exelixis reports 3Q loss
Yahoo/AP
Fri, 11/4/16 - 09:21 am
earnings
Exelixis
Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis
Motley Fool
Mon, 10/17/16 - 11:49 am
Pfizer
Bristol-Myers Squibb
Exelixis
Cabometyx
kidney cancer
Sutent
Opdivo
These 3 Little Biotechs Just Scored Big
Motley Fool
Tue, 10/11/16 - 09:33 pm
biotech
Celldex Therapeutics
melanoma
glemba
Exelixis
Cabometyx
renal cell carcinoma
Tesaro
ovarian cancer
niraparib
Exelixis and Pfizer drugs compete in kidney cancer trial
Yahoo/Reuters
Mon, 10/10/16 - 09:15 am
kidney cancer
Exelixis
Pfizer
Sutent
Cabometyx
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
Tue, 10/4/16 - 10:07 am
FDA
clinical trials
Exelixis
cabozantinib
Cobimetinib
Celldex Therapeutics
CDX-011
Cerulean Pharma
CRLX101
Medivation
Xtandi
Palatin
bermelanotide
Rexahn
RX-3117
Anthera Pharmaceuticals
Key FDA Decisions and Trial Results Coming in the Next 2 Months
24/7 Wall St
Wed, 09/14/16 - 11:53 pm
FDA
clinical trials
Array Biopharma
binimetinib
Mast Therapeutics
Novavax
RSV F vaccine
Threshold Pharmaceuticals
tarloxotinib
Cerulean Pharma
Vertex Pharmaceuticals
Orkambi
Exelixis
cabozantinib
Cobimetinib
Medivation
Xtandi
Celldex
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
Thu, 09/8/16 - 09:50 am
FDA
clinical trials
cabozantinib
Cobimetinib
Exelixis
Medivation
Xtandi
Celldex Therapeutics
glemba
Palatin
bremelanotide
CRLX101
Cerulean Pharma
Anthera Pharmaceuticals
Exelixis reports 2Q loss
Yahoo/AP
Thu, 08/4/16 - 09:47 am
Exelixis
earnings
Here's How Pfizer's Protecting Its Kidney Cancer Drug From New Competitors
Motley Fool
Sun, 07/10/16 - 11:59 am
Pfizer
Sutent
kidney cancer
Exelixis
Bristol-Myers Squibb
Novartis
4 Cancer Drug Developers You Need to Have on Your Radar This Year
Motley Fool
Wed, 06/15/16 - 10:33 am
cancer
Exelixis
Celldex Therapeutics
Ziopharm
Jazz Pharmaceuticals
Exelixis, Inc. Gets Some ASCO Love
Motley Fool
Tue, 06/7/16 - 11:16 am
Exelixis
ASCO 2016
Cabometyx
renal cell carcinoma
3 Big Pharma Stocks With Credible Threats to Their Blockbusters
24/7 Wall St
Fri, 05/6/16 - 10:52 am
Pfizer
renal cancer
Sutent
cabozantinib
Exelixis
AstraZeneca
Faslodex
breast cancer
Atossa Genetics
Merck
Zetia
Mylan Labs
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »